EGFR and non-small cell lung carcinoma: We also did not observed the significant association between BIM deletion polymorphism and incidences of rash, diarrhea, interstitial pneumonia and liver function damage due to TKI therapy among mutated-EGFR NSCLC cases, indicating that BIM deletion polymorphism could not be a predictor to evaluate toxic adverse event inducing by TKI in EGFR-mutated NSCLC patients.